by 10 days after implantation. Thus, the elevation in p-tau 2 months after implantation implies that the changes are quite persistent. Conclusion: Soluble A ␤ 1-42 oligomers have longlasting effects on tau phosphorylation in the rTg4510 model, possibly due to elevations in GSK3. These data suggest that even brief elevations in A ␤ production, may have enduring impact on the risk for tauopathy.
Introduction
In Alzheimer's disease (AD) and other tauopathy disorders, tau is involved in a series of pathological events, including hyperphosphorylation and aggregation into straight and paired helical filaments [1] , and finally, the formation of neurofibrillary tangles (NFT). The consequence of this process is disruption of microtubule assembly [2] and axonal transport [3, 4] , which ultimately may lead to neurodegeneration.
Transgenic mouse models expressing human tau mutations develop pathology that mimics frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) disorder, and have improved understanding of tau-mediated neurodegeneration [5, 6] . The inducible rTg4510 mouse model used here has demonstrated pro-gression of tau pathology with age, the formation of neurofibrillary tangles, cognitive impairment and neuronal loss [7, 8] . Understanding the mechanisms of cross-talk between tau and ␤ -amyloid (A ␤ ) has moved this area to the center of research efforts. It is still unclear in the literature whether the human amyloid precursor protein (hAPP)/A ␤ pathology is responsible for tau pathology in AD. Reports from studies of transgenic mouse models suggest that manipulation of A ␤ levels drives changes in the tau pathology [9] [10] [11] . Notably, the role of AD brainderived and synthetically prepared A ␤ oligomers in causing early synaptic toxicity [12, 13] , long-term potentiation deficits [14, 15] and cognitive dysfunction [16] supports a direct role of A ␤ 1-42 -derived oligomers in the early pathology of disease. However, other reports suggest that reduction of endogenous tau levels protects against excitotoxicity in vitro [17] and prevents A ␤ -related behavioral deficits in transgenic mice expressing human APP, potentially via tyrosine kinase Fyn activation [18, 19] . Moreover, a dendritic role of tau in conferring Fyn-mediated A ␤ toxicity was suggested as a possible mechanistic explanation of the A ␤ , tau and Fyn triad [20] .
In the present study, we examined the effect of acute or chronically infused synthetic oligomeric A ␤ 1-42 on phosphorylated (p)-tau levels in 5-month-old rTg4510 mice. The questions we wished to address concerned (a) the dwell time of oligomeric A ␤ after intracranial administration, (b) the impact of the A ␤ oligomers on tau metabolism and its persistence in the early stages of tauopathy and (c) the relationship of these changes to kinase activity and microglial activation. Our findings are consistent with the accumulating body of evidence that A ␤ oligomers exacerbate tau pathology in vivo.
Materials and Methods

Production and SDS-PAGE/Immunoblotting of Oligomers
Oligomers of A ␤ 1-42 were prepared as described previously [21] . For initial characterization, A ␤ 1-42 peptide (Biosource, Camarillo, Calif., USA) was dissolved in ice-cold hexafluoroisopropanol and thoroughly mixed. Aliquots were taken, the hexafluoroisopropanol was completely evaporated, and samples were frozen at -80 ° C until use. For oligomer preparations, the dried A ␤ was first dissolved in 100% DMSO to 5 m M A ␤ , then 50-fold diluted with F12 medium (PromoCell, Heidelberg, Germany) supplemented with 146 mg/l glutamine (PromoCell) to obtain 100 M of A ␤ solution. Samples were incubated for 24 h at 4 ° C and then centrifuged at 14,000 g for 10 min at 4 ° C to remove large aggregates. The size distribution of the oligomers in the supernatant was examined by atomic force microscopy (AFM).
The 100-M A ␤ 1-42 sample prepared as described above was incubated for 30 days inside a microosmotic pump (Alzet No. 1004; Durect, Cupertino, Calif., USA) at 37 ° C in PBS (pH 7.4). Due to the properties of the osmotic pump, we were able to collect aliquots of oligomers pumped from the reservoir at various time points. Aliquots were diluted 10-fold, and applied to SDS-PAGE as previously described [22] . Monoclonal mouse antibody 6E10 against A ␤ was used (Convance, Dedham, Mass., USA; 1: 1,000 dilution). Immunostained proteins were visualized using chemiluminescence, in accordance with the manufacturer's recommendations (ECL; SignaGen Laboratories, Gaithersburg, Md., USA).
Physical Characterization of the Oligomeric Solution AFM (XE-100; PSIA, Santa Clara, Calif., USA) was used to determine the morphology of the species present in the A ␤ 1-42 oligomeric solution. Silicon nitride with aluminum coating (Tap300Al-G; Budget Sensors, Sofia, Bulgaria) cantilevers with 300-kHz frequency and 40 N/m force constant were used in this study. The images were collected at a scan rate of 1 Hz/min and gain 1. Five microliters of the oligomeric solution were deposited on freshly cleaved mica at a concentration of 25 M , incubated for 5 min, rinsed with Millipore water and dried with ultrapure nitrogen (NI UHP300; Airgas, Tampa, Fla., USA). The samples were imaged using tapping mode to preserve their integrity.
Mice
The rTg4510 mice originate from the mouse model of tauopathy described elsewhere [8] . Both rTg4510 mice and the littermate control mice that do not express tau were used between 3 and 5 months of age. Animals were housed and treated according to institutional and National Institutes of Health standards.
Stereotaxic Intracranial Injections and Infusion of A ␤ 1-42 Oligomers
Acute injections of 100 M of oligomers or scramble A ␤ 1-42 into the cortex and hippocampus of 5-month-old rTg4510 and age-matched nontransgenic (ntg) littermates were performed using the convection-enhanced delivery method described previously [23] . The injection coordinates were as follows: hippocampus, anteroposterior, -2.7 mm; lateral -2.7 mm, vertical -3.0 mm from bregma; cortex, anteroposterior, +1.7 mm; lateral -2.2 mm, vertical -3.0 mm from bregma. Ntg mice injected with oligomers were sacrificed 1 h after intracranial injection to visualize the injected material, while rTg4510 injected with oligomers or scrambled A ␤ 1-42 survived for 3 days. The chronic infusion of human A ␤ 1-42 oligomers or saline into 3-month-old rTg4510 and ntg mice was performed as described previously [24] . Briefly, a cannulae (Plastics One, Roanoke, Va., USA) was stereotactically implanted into the right hippocampus (coordinates from bregma: -2.7 mm anteroposterior; -2.7 mm lateral; 3.0 mm vertical), and an osmotic pump (Alzet No. 1004; Durect, Cupertino, Calif., USA) was attached and implanted subcutaneously near the scapula. Pumps contained either oligomeric A ␤ 1-42 (Biosource) in vehicle (F12 medium) or saline alone. The infusion rate was 0.11 l/h (67 ng/h A ␤ 1-42 ). Pumps remained in place for A ␤ delivery for 28 days, and mice were sacrificed 1 month after the termination of the infusion (2 months after pump placement).
Immunohistochemistry/Immunofluorescence
Immunohistochemistry was performed on free-floating sections collected from brain tissue and prepared as described in detail previously [25] . Sections were incubated with primary an-tibodies ( table 1 ) overnight at 4 ° C, washed and incubated with either goat anti-rabbit IgG Alexa 594, streptavidin-Alexa 488 (Invitrogen, Carlsbad, Calif., USA) for immunofluorescence or with the appropriate biotinylated secondary antibody for immunohistochemistry (Vector Laboratories, Burlingame, Calif., USA) for 2 h at room temperature. For immunohistochemistry, sections were incubated for 1 h in avidin-biotin complex (Vectastain Elite; Vector Laboratories) and washed. Color development was performed using 3,3 -diaminobenzidine (DAB; Sigma, St. Louis, Mo., USA) enhanced with nickelous ammonium sulfate (Baker, Phillipsburg, N.J., USA). Staining was analyzed with a digital scanning microscope (Mirax) and quantified by the Zeiss Image HIS segmentation analyzing program (Zeiss, Göttingen, Germany). For immunofluorescence, sections were mounted on slides and imaged using a Zeiss AxioVision Imager Z1 microscope and processed using AxioVision 4.8 image software.
Statistics
Statistical analyses were performed using Student's t test or one-way ANOVA followed by Fisher's post hoc least-significant difference (PLSD) test for the comparison of means using StatView software (version 5.0; SAS Institute, Cary, N.C., USA). Graphs were generated using GraphPad Prism 4.0 (La Jolla, Calif., USA).
Results
A ␤ 1-42 Oligomer Characterization
Based on results suggesting a link between amyloid and tau pathology [10, 26, 27] , we administered oligomers of A ␤ 1-42 into rTg4510 mice. Oligomeric species were prepared using defined conditions described previously [21] . Western blotting and AFM were used to determine the secondary structure of A ␤ 1-42 -derived oligomers. Figure  1 a shows the bands identified on the SDS-PAGE and Western blot. The preparation contains a mixture of low (LMW, 17-14 kDa) and high-molecular-weight oligomers (HMW, 38-180 kDa) as well as the monomer. We exploited AFM to investigate the physical features of the oligomers after a 24-hour incubation at 37 ° C. As shown in figure 1 b, most of the 24-hour incubation samples contained globular structures with a mean diameter of 22 nm and a height of 2.8 nm.
A ␤ Oligomers after Injection into the Mouse CNS To monitor the distribution of A ␤ oligomers after injection into mouse brain, we performed acute injections into the anterior cortex and hippocampus unilaterally and monitored the dispersion of the injected material using immunohistochemistry. When tissue was collected 1 h after the intracerebral injection, we found extensive diffusion of A ␤ from the sites of injection (arrowheads, fig. 2 a) with some distribution into the striatum after cortical injection and to the entorhinal cortex after hippocampal injection. There was no immunostaining visible in the uninjected hemisphere (left, fig. 2 b) , suggesting that the injected material did not cross the midline. However, in tissue collected 3 days after the acute injection, we were unable to detect A ␤ oligomers in any brain region ( fig. 2 b) . Acute injection of oligomers (OLIGO) did not affect p-tau levels. Immunoreactivity of S202/T205, S396, S199/S202 p-tau and total tau immunoreactivity in the ipsilateral frontal cortex (CX) and CA1 field of the hippocampus ( a-p ) of rTg4510 mice injected with scrambled (Sc) A ␤ (n = 5) or OLIGO (n = 5) are shown. The levels of total tau or p-tau were undetectable in the ntg mice injected with OLIGO preparations and hence were not shown. Staining intensity was analyzed as percent of stained area for each region and represented as ratio of the ipsilateral to contralateral side ( q-t ). Data from the frontal CX are presented on the left, while data from the hippocampus (HPC) are presented on the right. There were no statistically significant changes in staining for any tau marker. Statistical comparisons by Student's t test were performed using StatView software. Tissue was stained for A ␤ immunoreactivity.
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Hence, we concluded that oligomeric A ␤ 1-42 was quickly cleared/degraded from the animal's brain. Thus, for protracted exposure of the brain to oligomeric A ␤ , it would seem that a more sustained infusion would be required.
Pathological p-Tau Was Not Altered by Acute Administration of A ␤ 1-42 Oligomers
We subsequently performed immunohistochemical studies and image analyses to determine the levels of ptau in rTg4510 mice injected with oligomeric A ␤ 1-42 compared with scramble A ␤ using murine littermates ( fig. 3 ) . Multiple p-tau epitopes [serine (S)202 /threonine (T)205, S396 and S199/S202] as well as total tau were evaluated. The total tau antibody recognizes an epitope in the N terminus of human tau independent of phosphorylation. ptau staining in the anterior cortex ( fig. 3 a, b , e, f, i, j) and CA1 field of the hippocampus ( fig. 3 c, d , g, h, k, l) were readily detected by immunohistochemistry in rTg4510 mice. However, injection of oligomers did not alter p-tau levels in either region measured with any marker when compared to mice injected with the scrambled A ␤ peptide as a control for the injection procedure ( fig. 3 q-s) .
Similar results were observed when comparing p-tau levels in injected versus uninjected hemispheres (data not shown). Acute injections of A ␤ 1-42 oligomers did not produce striking changes in total tau staining ( fig. 3 m-p) , and this was reflected in image analysis measurements of immunostaining ( fig. 3 t) .
Acute A ␤ 1-42 Oligomer Injection Was Associated with Alternations in GSK3 Activity
Given the direct effect of GSK3 (glycogen synthase kinase-3) on tau pathology [28] we evaluated whether acute oligomer injections affect GSK3 activity in this model. Staining for pGSK3 ␣ / ␤ kinase at pY279/pY216 increased after acute injections of oligomers in the brain of rTg4510 mice compared with mice injected with scrambled A ␤ in the anterior cerebral cortex ( fig. 4 a, c) and the CA1 area of the hippocampus ( fig. 4 b, d ). Quantification revealed that oligomeric A ␤ 1-42 injection significantly induced pGSK3 ␣ / ␤ levels compare to scrambled A ␤ 1-42 in both the frontal cortex ( fig. 4 e, * p ! 0.05) and hippocampus ( fig. 4 f, * * p ! 0.01) of rTg4510 mice. 
Staining intensity was analyzed as percent of stained area and presented as ratio of the ipsilateral to the contralateral side for each region after treatment ( e , f ). Student's t-test: * p ! 0.05; * * p ! 0.01, n = 5.
Acute Injection of A ␤ 1-42 Oligomers Did Not Exacerbate the Microgliosis Present in rTg4510 Mice
Acute injections of oligomeric A ␤ did not modify the activation state of microglia, assessed by either CD45 ( fig. 5 ) or CD68 immunostaining ( fig. 6 ). Although the data presented here compare the hemispheres injected with oligomeric A ␤ and scrambled A ␤ peptide, similar findings were true in comparisons between the oligomeric A ␤ -injected hemisphere and the contralateral hemisphere (not shown).
Chronic Infusion of A ␤ 1-42 Oligomers in rTg4510 Mice Enhances Phosphorylation of Tau
Although acute administration of A ␤ oligomers had no impact on p-tau, it is less clear what the impact of longer exposure would be. We infused a solution containing 100 M A ␤ 1-42 oligomers or saline (as a surgical control) into the right hippocampus of 3-month-old rTg4510 mice for 28 days using osmotic minipumps and indwelling intracranial cannulae. We also infused oligomeric A ␤ into ntg animals lacking human tau. We then collected tissue 60 days after pump implantation, to ascertain if there were any enduring effects of the A ␤ oligomers on histopathology in the rTg4510 mice.
We evaluated several p-tau epitopes ( table 1 ) in the CA1 field of the hippocampus and entorhinal cortex. S199/202 p-tau was localized to neuronal cell bodies of the pyramidal cells of CA1 ( fig. 7 c, e) as well as to neurons in the entorhinal cortex ( fig. 7 d, f) in rTg4510 mice. Infusion of oligomers into the hippocampus increased p-tau S199/202 in this region compared to saline-treated rTg4510 animals ( fig 7 c , e, g; p ! 0.01). A trend toward increased S199/202 p-tau level was observed in the entorhinal cortex, but did not reach significance ( fig. 7 d, f,  h ). Injection of oligomers in ntg mice did not result in phosphorylation of S199/202 epitopes of endogenous mouse tau ( fig. 7 a, b ; not quantified due to signal absence).
Similar results were observed for p-tau S202/T205 staining. In saline-treated rTg4510 mice, p-tau S202/ T205 was localized to neuronal soma of pyramidal and cortical neurons (inset, fig. 8 a, c) . Interestingly, p-tau at the S202/T205 epitope in oligomer-treated mice displayed somatodendritic localization in pyramidal CA1 neurons (inset, fig. 8 c) . Oligomers dramatically increased the levels of p-tau S202/T205 in the right hippocampus of rTg4510 mice compared to the saline-treated group ( fig. 8 e; p ! 0.01). In contrast, infusion of oligomeric A ␤ did not significantly induce p-tau S202/T205 in the entorhinal cortex areas compared to saline-infused animals ( fig. 8 f) . Based on the evidence of the involvement of tau phosphorylated at S396 in modifying microtubule binding and promoting neuronal degeneration [29] , we evaluated the pS396 levels as an indicator of tau pathology. Significantly increased levels of pS396 tau were observed in the right hippocampus of oligomer-versus saline-treated rTg4510 groups ( fig. 9 c, e, g; p ! 0.05). Furthermore, A ␤ oligomer infusion did not induce significant changes in p-tau levels in the entorhinal cortex ( fig. 9 d, f, h ).
We investigated total tau expression using an antibody which recognizes an N-terminal domain epitope of human tau irrespective of the phosphorylation status ( fig. 10 ). We were unable to detect tau in the ntg mice with this antibody ( fig. 10 a, b) . Total tau was localized in the neuron cell body and oligomer delivery did not significantly affect total tau levels in rTg4510 mice compared to the saline-treated cohort ( fig. 10 c-h) . Similarly, staining for another paired helical filament-tau epitope, pS356, demonstrated p-tau somatic localization in neurons, but no significant effect of oligomers was observed between groups (data not shown).
GSK 3 Is Elevated in the rTg4510 Model and in Response to A ␤ 1-42 Oligomers
In rTg4510 mice, A ␤ oligomer infusion augmented pGSK3 immunoreactivity in the hippocampus compared to the saline-treated group ( fig. 11 a, c, e, g; p ! 0.05). In spite of increased levels of pGSK3 in rTg4510 mice compared to the ntg group in the entorhinal cortex ( fig. 11 b, d) , the dif- ference between saline-and oligomer-injected rTg4510 mice did not achieve statistical significance (note the neuronal localization of pGSK/activated GSK3 in figure 11 ).
Finally, we looked at the relationship between activated GSK3 and p-tau in rTg4510 mice. We used immunofluorescence to co-localize S202/T205 p-tau ( fig. 12 a, e) and pGSK3 ( fig. 12 b, e) in the tissue from oligomer-injected rTg4510 mice. Immunofluorescent staining revealed a considerable degree of co-localization of GSK3 with AT8 p-tau in the CA1 ( fig. 12 a-c) and entorhinal cortex ( fig. 12 d-f ). Both markers appeared to be located to the perinuclear area, as shown by the merged images with nuclear DAPI staining ( fig. 12 c, f) .
CD68-Positive Microglia but Not CD45 Microglia following Chronic A ␤ 1-42 Oligomer Infusion
Intracerebral injection of A ␤ aggregates and derived oligomers has been linked with increased microgliosis [24] . We stained for CD45 and CD68 to monitor microglial activation. Consistent with our group's previous observations [30] , at 5 months of age, the presence of tau pathology in rTg4510 mice is accompanied by increased CD45 immunoreactivity compared with ntg mice ( fig. 13 a, b) . After oligomer infusion, the microglial morphology showed a trend towards a more activated phenotype, with enlarged somata and thickened processes ( fig. 13 e) compared to saline-injected mice ( fig. 13 c) . However, statistically significant differences in the immunostained area were observed in the hippocampus in comparison to the ntg mice ( fig. 13 a, g ). This suggests that the CD45 expression of activated microglia in rTg4510 mice is tau pathology-related and independent of oligomer administration. These results were in agreement with the acute effects of oligomers on CD45-activated microglia ( fig. 5 ) .
We did not observe activation of CD68 phagocytic microglia in ntg oligomer-infused animals ( fig. 14 a, b) . Moreover, rTg4510 infused with saline displayed modest amounts of CD68 immunoreactivity ( fig. 14 c, d ). Chronic infusion of oligomers induced activation of CD68 phagocytic microglia ( fig. 14 e, f) . Image analysis showed that A ␤ oligomer infusion significantly increased CD68 expression in the hippocampus ( fig. 14 g; p ! 0.05) and entorhinal cortex ( fig. 14 h; p ! 0.05) compared to both ntg and rTg4510 saline-infused animals. We also examined another microglial marker, CD11b, and an astrocyte marker, glial fibrillary acidic protein (GFAP), by immunofluorescence. We observed an increase in CD11b+ microglia in the hippocampus of rTg45140 animals chronically infused with oligomers (red, online supplementary fig. 1C ; for all online supplementary material, see www.karger.com/doi/10.1159/000337230) compared to the saline controls (online suppl. fig. 1A ), with less effect in the entorhinal cortex (online suppl. fig. 1B vs. D) . However, no changes in astrocytosis were observed as shown by GFAP immunohistochemistry analysis (green, online suppl. fig 1E-H) . Merging of the CD11b and GFAP images indicated little overlap of these two distinct populations of cells (microglia and astrocytes).
Stability of Oligomeric A ␤ within the Minipump
To monitor structural changes in the injected sample, the same oligomer preparation used for the intracranial injections was loaded into an osmotic pump kept under physiological conditions (isotonic buffer at 37 ° C), and samples were collected after 1, 10 or 27 days of incubation. Interestingly, after 1 day of incubation within the pump, the monomeric species decreased precipitously and a clus- ter of LMW material appeared, primarily migrating at a molecular weight consistent with trimers (online suppl. fig. 2 ). HMW oligomers (38-to 180-kDa bands) were present at all the sampling times, but decreased during the 27-day incubation period. Large aggregates were also visible at the top of the gel and continued to be present up to 10 days (data not shown). Western blot data suggested that oligomers kept ex vivo but inside the osmotic pump contain a mixture of oligomer species. On day 27, the solution exiting the pump contained little A ␤ protein. It is possible that this hydrophobic protein adhered to the inside of the osmotic pump or aggregated and precipitated in a manner that prevented additional release from the pump.
Discussion
Several lines of evidence suggest that A ␤ pathology precedes and can potentiate tau pathology. First, it is generally regarded that the initial pathology to develop in AD patients is A ␤ deposition, and this is followed by tau pathology with several years delay [ 31 , but see ref. 32 for a different perspective]. Second, mutations in tau do not recapitulate the pathological or behavioral correlates of AD [33] , while mutations affecting the APP or its processing do reproduce most features associated with sporadic AD [34] . Moreover, in AD the brain regions developing tau pathology are, at least sequentially, distinct from those brain regions affected by other tauopathies. This leads to the suggestion that one consequence of amyloid deposition in AD may be to precipitate tau pathology. Similar evidence of A ␤ -induced exacerbation of tau pathology is accumulating in studies in animal models. Geula et al. [35] observed that intracranial injections of fibrillar but not soluble A ␤ could initiate tau pathology in aged marmosets (this was prior to attempts to isolate oligomeric forms of A ␤ ). Forebrain tau pathology has been shown to be enhanced by A ␤ administration in tau transgenic mouse models [10, 27] . More recently, injection of aged APP brain extract into the brain of young B6/ P301L mice was also shown to increase tau pathology [9] . Immunotherapeutic approaches or genetic modifications which reduce A ␤ accumulation slow the development of tau pathology in models exhibiting both pathologies [36, 37] . Furthermore, studies suggest a postsynaptic role for tau in conferring A ␤ effects on cognitive function [18] and dendritic toxicity [20, 38] .
In this experiment, we examined the impact of acute versus chronic administration of A ␤ 1-42 oligomers in tau phosphorylation. First, we investigated the composition of the A ␤ 1-42 oligomers that were used for in vivo infusion. The A ␤ oligomer sample initially contained a mixture of LMW forms with stable, globular structures; A ␤ oligomers are cleared and/or degraded from brain parenchyma within days ( fig. 2 ) , consistent with earlier work using nonfibrillar forms of A ␤ [39, 40] . Study of the ma- terial exiting from the pumps revealed that larger aggregates predominated if the material was incubated at 37 ° C in physiological buffer inside the osmotic minipump. This observation is in agreement with data published previously showing metastable structures of A ␤ with increased temperature [21] . This led to either precipitation of the aggregates or adsorption of the material onto the lining of the pump chamber or polyethylene tubing. In either case, these results indicate that the infusion of A ␤ oligomers was largely complete by 10 days after pump implantation. Without the inclusion of this in vitro control condition in the study, we would not have discovered this early termination of A ␤ infusion.
For these experiments, we selected the age of 5 months in the rTG4510 model because this is a time when some tau pathology is evident but not maximal [8, 41] . Acute injections of A ␤ oligomers did not alter the p-tau levels at any of the epitopes investigated in vivo at the 3-day postinjection interval ( fig. 3 ) . We selected this interval as one in which we have previously observed effects of intracranially administered agents [42] [43] [44] [45] . It is unclear whether the lack of effect indicates that none had yet developed, or that the clearance of A ␤ led to rapid reversal of p-tau changes that might have occurred. This is in contrast to the recent evidence of an acute effect of A ␤ oligomers on tau phosphorylation in cultured hippocampal neurons [46] . Whether this represents true differences between in Color version available online Fig. 13 . CD45 immunoreactivity is prominent in rTg4510 mouse brain and independent of oligomer (OLIGO) infusion. Micrographs represent CD45 immunoreactivity in the CA1 region of the hippocampus (HPC) and entorhinal cortex (EC) of OLI-GO-infused ntg mice ( a , b ), and rTg4510 mice following saline ( c , d ) or OLIGO infusion ( e , f ). Staining intensity was analyzed as percent of stained area for each region ( g , h ). Statistical comparisons by one-way ANOVA and Fisher's PLSD were performed using StatView software. * p ! 0.05, n = 6. vitro and in vivo models, or is a product of the reduced magnitude of effect in vivo is not clear at this stage. However, a key observation in the mice injected acutely with A ␤ oligomers was a significant increase in the active form of GSK3, a kinase capable of phosphorylating multiple sites on tau [47, 48] .
Unlike the acute treatment, chronic infusion of A ␤ oligomers increased p-tau in vivo. Staining for p-tau using several antibodies (pS199/S202, pS202/T205 and pS396) was elevated 3-to 4-fold in the injected hippocampus ( fig. 7 , 9 ) compared to the saline-treated rTg4510 group. Although the adjacent entorhinal cortex indicated a trend towards an increase, this was not statistically significant. No differences were observed contralateral to the side of injection. The pS396 epitope is suggested to be involved in microtubule destabilization and paired helical filament formation in AD brain [29] . However, not all forms of tau were elevated. Total tau and the pS356-specific antibody were unaffected by the A ␤ oligomer treatment. It is important to note that these effects are enduring, as the infusion of A ␤ oligomers probably ceased 6 weeks prior to tissue collection. This observation implies that even transient stimulation of tau pathology can have long-lasting impact on the rate of tauopathy development, and at some stage these changes are irreversible (consistent with suppression of the transgene with doxycycline [8] ).
Perhaps most intriguing was the persistence of the GSK3 activation induced by the injection of A ␤ oligomers into the hippocampus. As in the acute study, the phosphorylation and activation of this enzyme persists after the injected A ␤ has been cleared from the brain ( fig. 11 ) . Moreover, there is a large degree of overlap between cells expressing elevated pS202/T205 and GSK3, implying that this elevated kinase expression may be responsible for the increased p-tau. During both brain development and in neurodegenerative diseases, activated GSK3 is associated with hyperphosphorylated tau and the two markers are co-localized within neurons [49] . Consistent with our findings, in vitro [50] and in vivo studies [51] report A ␤ oligomer-induced tau pathology through active GSK3 ␣ / ␤ . To our knowledge, this is the first report that the activation of GSK3 ␣ / ␤ kinase by A ␤ oligomers persists beyond the period of direct exposure to the A ␤ . This may be one mechanism by which shortterm elevations in A ␤ , e.g. following head injury [52] , can increase the risk for subsequent tauopathy.
We previously demonstrated the role of potent inflammatory stimuli, e.g. lipopolysaccharides, on exacerbating tau pathology [30] . Furthermore, we reported that increases in several markers of microglial activation were dependent on age and pathological tau accumulation in rTg4510 mice [30] . Our data show two important findings: (1) rTg4510 mice exhibit microglial activation (measured with CD68) compared to ntg animals independent of acute exposure to the oligomers and (2) chronic infusion of A ␤ 1-42 oligomer exacerbates microglial activation. A straightforward interpretation of these data is that the p-tau pathology resulted in microglial overexpression of CD68. Interestingly, our data demonstrate that CD45-immunoreactive microglia were not affected by either acute or chronic administration of oligomers in the brain. This is quite distinct from observations in mice with amyloid deposits [25] . Given the suggestion that CD45-high immune-positive cells are derived from infiltrating monocytes [53] , this would suggest that tau pathology does not lead to significant recruitment of blood-derived cells.
In conclusion, we demonstrate evidence for the involvement of A ␤ -derived oligomers in modifying the level of hyperphosphorylated tau. The neuropathological symptoms of AD are multifactorial and many kinases and molecular mechanisms contribute to the disease; however, we demonstrate here persistently increased phosphorylation/activation of GSK3 ␣ / ␤ in both acutely and chronically A ␤ oligomer-treated rTg4510 mice. These data would suggest that GSK3 inhibitors may be effective in diminishing some of the effects of A ␤ oligomers on exacerbation of tau pathology.
